Exendin-4, liraglutide, and GLP-1 analog with Ala8Val substitution enhanced long-term potentiation in the brain and reduced the number of amyloid dense-core plaques in mice with insulin resistance and in patients with T2DM-associated obesity and Alzheimer's disease [69]. This evidence concerns the gene GCG and type 2 diabetes mellitus.